- Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
null null et al, 2021, Cochrane Database of Systematic Reviews CrossRef - CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
Augusto Rojas-Martinez et al, 2022, Current Gene Therapy CrossRef - Monitoraggio delle complicanze da tossicità nei pazienti sottoposti a CAR-T: studio osservazionale, prospettico
Francesca Palmisano et al, 2022, Working Paper of Public Health CrossRef - Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals
Anna Sureda et al, 2024, Future Oncology CrossRef - IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
Huihui Zhang et al, 2022, Human Vaccines & Immunotherapeutics CrossRef - Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Ding-Kang Wang et al, 2021, Frontiers in Immunology CrossRef - Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis
Sabine Seidel et al, 2023, Neurological Research and Practice CrossRef - Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
Ying Li et al, 2024, Frontiers in Immunology CrossRef - Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy
Cecilia C. S. Yeung et al, 2024, European Journal of Haematology CrossRef - IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
Sheridan L. Swan et al, 2023, Frontiers in Immunology CrossRef - PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
Chenggong Li et al, 2021, Frontiers in Immunology CrossRef - Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience
B Čemusová, 2022, Anesteziologie a intenzivní medicína CrossRef - Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I. Gordon et al, 2023, Oncotarget CrossRef - Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
Min Yu et al, 2023, Human Gene Therapy CrossRef - Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
Irit Avivi et al, 2022, Annals of Hematology CrossRef